Hester Biosciences Ltd Q4 FY26 Earnings Analysis

- The company aims to sustain and grow its Poultry Healthcare business, supported by deeper market penetration, improved placement, and stronger distribution coverage. - Post Q3 FY26, regulatory approval of the H9N2 Avian Influenza vaccine positions the company well for both domestic and export growth. - Expansion of manufacturing capacity through capitalized fill/finish facility will support scale-up of existing products and introduction of new products. - Animal Healthcare division is expected to gain momentum in Q4 FY26 with the commencement of government immunization programs (PPR and Goat Pox) after prior delays. - Focus on reducing dependency on tender-based revenues by increasing direct sales to commercial and export markets. - Long-term growth underpinned by ongoing innovation, technological depth, and strategic initiatives to leverage capacity and market opportunities. - EBITDA and profitability are expected to improve year-on-year, reflecting operational discipline and better product mix management.

- Management is confident about sustaining and improving growth, particularly in the Poultry Healthcare division. - EBITDA is currently around INR 20 crores quarterly, with expectations of a higher trajectory year-on-year. - Profitability improvements are driven by favorable product mix, operational discipline, and better execution. - Long-term capex and capacity expansion, such as doubling fill/finish facility capacity, are aligned to support scale-up and revenue growth. - Animal Healthcare segment faces timing delays, notably government immunization programs resuming from February 2026, expected to improve momentum in Q4. - Expansion into new products like H9N2 Avian Influenza vaccine and enhancement of portfolio position the company for future growth. - The company aims to reduce dependence on tender business and deepen presence in commercial and export markets. - Overall, management anticipates stronger, more balanced financial performance with sustained EBITDA and profit growth moving forward.

- The company has capitalized a fill/finish facility, effectively doubling drug product capacity. - Remaining capital work in progress (CWIP) worth INR 182 crores is expected to be capitalized over the coming months. - Capex is structured in phases to support scale-up across products and markets, with progressive returns as utilization increases. - No current plans for contract manufacturing or innovator-led manufacturing; focus remains on retaining brand and exporting directly. - The BSL-3 facility originally for COVID vaccine production is being evaluated for repurposing into an animal vaccine manufacturing facility; specifics are yet to be finalized. - Petcare segment expansion is underway without incremental capex, leveraging existing facilities for potential vaccine opportunities. - Overall strategic focus on capacity strengthening, reducing tender dependence, and supporting future growth through measured capex investment.

- No explicit mention of any current or future fundraising plans through debt or equity was made during the call. - The company discussed ongoing capital expenditure (capex) investments, including capitalization of their fill/finish facility and INR182 crores capital work in progress, but these are being funded internally. - There was focus on scaling existing capacities, product launches, and improving operational efficiency without reference to raising funds. - Management emphasized operational discipline and long-term growth but did not indicate plans to raise external funds via equity or debt in the near term.

- No specific details or figures about the current or expected order book or pending orders were disclosed in the transcript. - The management discussed ongoing efforts to reduce dependence on tender-based revenues and increase direct sales in both domestic and export markets. - Institutional orders, especially in Africa, are subject to timing delays linked to government-led immunization program funding releases and rollout schedules. - The company reported that the delay in immunization programs (like PPR and goat pox vaccines) affected Animal Health segment revenues but is expected to resume from February 2026 with improved momentum. - Overall, the focus remains on steady execution, capacity strengthening, and building a more balanced and resilient business, implying a stable order flow aligned with these strategies.